Rockefeller Capital Management’s Taysha Gene Therapies TSHA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$24.4K Hold
5,000
– – ﹤0.01% 3821
2026
Q2
$34K Hold
5,000
– – ﹤0.01% 3533
2026
Q1
$22.4K Hold
5,000
– – ﹤0.01% 3670
2025
Q4
$27.5K Hold
5,000
– – ﹤0.01% 3356
2025
Q3
$16.4K Buy
+5,000
New +$14.2K ﹤0.01% 3437

Other funds holding TSHA

Rockefeller Capital Management's TSHA Position: Q3 2026 in Review

Rockefeller Capital Management held its Taysha Gene Therapies (TSHA) position steady in Q3 2026 at 5,000 shares worth $24.4K. The position accounts for ﹤0.01% of the portfolio, ranked #3821.

Rockefeller Capital Management first reported a position in TSHA in Q3 2025 and has held it in 5 quarters since. The position peaked at $34K in Q2 2026. 135 funds tracked by Wall St. Rank hold TSHA as of Q3 2026.

  • Rockefeller Capital Management held 5,000 shares of Taysha Gene Therapies worth $24.4K as of Q3 2026.
  • Rockefeller Capital Management left its Taysha Gene Therapies share count unchanged in Q3 2026.
  • Taysha Gene Therapies made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q3 2026, its #3821 holding.
  • Rockefeller Capital Management first reported a position in Taysha Gene Therapies in Q3 2025 and has held it in 5 quarters since.
  • Rockefeller Capital Management's Taysha Gene Therapies position peaked at $34K in Q2 2026.
  • 135 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q3 2026.

Based on Rockefeller Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.